The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit
Open accessAbstract
A hypoxic state is critical to the metastatic and invasive characteristics of cancer. Numerous pathways play critical roles in cancer maintenance, many of which include noncoding RNAs such as microRNA (miR)-210 that regulates hypoxia inducible factors (HIFs). Herein, we describe the identification of a small molecule named Targapremir-210 that binds to the Dicer site of the miR-210 hairpin precursor. This interaction inhibits production of the mature miRNA, derepresses glycerol-3-phosphate dehydrogenase 1-like enzyme (GPD1L), a hypoxia-associated protein negatively regulated by miR-210, decreases HIF-1α, and triggers apoptosis of triple negative breast cancer cells only under hypoxic conditions. Further, Targapremir-210 inhibits tumorigenesis in a mouse xenograft model of hypoxic triple negative breast cancer. Many factors govern molecular recognition of biological targets by small molecules. For protein, chemoproteomics and activity-based protein profiling are invaluable tools to study small molecule target engagement and selectivity in cells. Such approaches are lacking for RNA, leaving a void in the understanding of its druggability. We applied Chemical Cross-Linking and Isolation by Pull Down (Chem-CLIP) to study the cellular selectivity and the on- and off-targets of Targapremir-210. Targapremir-210 selectively recognizes the miR-210 precursor and can differentially recognize RNAs in cells that have the same target motif but have different expression levels, revealing this important feature for selectively drugging RNAs for the first time. These studies show that small molecules can be rapidly designed to selectively target RNAs and affect cellular responses to environmental conditions, resulting in favorable benefits against cancer. Further, they help define rules for identifying druggable targets in the transcriptome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
A MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055
Distinguishing protein-coding and noncoding genes in the human genome
Clamp, M., Fry, B., Kamal, M., Xie, X., Cuff, J., Lin, M. F., Kellis, M., Lindblad-Toh, K., & Lander, E. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709013104 · Cited by 624
Cited by
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Principles for targeting RNA with drug-like small molecules
Warner, K. D., Hajdin, C. E., & Weeks, K. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.93 · Cited by 749
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
The Regulatory Role of MicroRNAs in Breast Cancer
Loh, H.-Y., Norman, B. P., Lai, K.-S., Rahman, N. M. A. N. A., Alitheen, N. B. M., & Osman, M. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194940 · Cited by 326
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Metadata
- Authors
- Costales, M. G., Haga, C. L., Velagapudi, S. P., Childs-Disney, J. L., Phinney, D. G., & Disney, M. D.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-02-27
- Volume
- 139
- Issue
- 9
- Pages
- 3446-3455
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W2591668896
- Cited by
- 164
- References
- 4
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. https://app.cochat.ai/papers/10.1021/jacs.6b11273
- The paper
- Costales, M. G., Haga, C. L., Velagapudi, S. P., Childs-Disney, J. L., Phinney, D. G., & Disney, M. D. (2017). Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6b11273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.